Missed, Minimized, and Misread: The Systemic Failure to Identify Co-Occurring Disorders in Women

When Priya was thirty-one, she told her primary care physician that she had been drinking a bottle of wine most nights and that she couldn't stop crying. Her doctor referred her to a therapist for depression and suggested she "cut back" on alcohol. It was four more years before anyone used the words "alcohol use disorder." It was five years before anyone connected the alcohol use disorder to the anxiety and depression and offered her a treatment plan that addressed all three at once.

Priya's story is not exceptional. It is, according to the available data, close to typical.

Research published in the Journal of Substance Abuse Treatment and elsewhere consistently documents a gender-based diagnostic lag in dual diagnosis identification—a pattern in which women with co-occurring mental health and substance use disorders reach integrated diagnosis and treatment substantially later than men with comparable symptom profiles. Understanding why this happens requires looking at the clinical, cultural, and structural forces that shape how women's symptoms are perceived, recorded, and acted upon.

Different Roads to the Same Intersection

One of the most significant reasons women are diagnosed later is that they often arrive at dual diagnosis through different pathways than men—pathways that the clinical system is not always equipped to recognize.

Men with dual diagnosis more frequently present through channels that trigger rapid addiction assessment: emergency departments following overdose or injury, criminal justice referrals, or acute psychiatric crises that involve visible behavioral dysregulation. These presentations are hard to overlook. They produce documentation, referrals, and clinical attention.

Women, by contrast, are more likely to present in primary care settings complaining of anxiety, fatigue, sleep problems, or diffuse physical symptoms. Their substance use—which research suggests is more likely to involve prescription medications, alcohol consumed privately, or patterns that began in response to trauma or emotional pain—is less visible in these settings and less likely to be probed. The clinical encounter is oriented toward the presenting complaint, and the substance use remains in the background, unasked about and undisclosed.

This phenomenon, sometimes described in the literature as "telescoping," refers to the observation that while women typically initiate substance use later than men, they progress from first use to dependence more rapidly and experience more severe medical and psychiatric consequences at lower levels of consumption. The clinical system, designed around male norms of addiction progression, may not recognize that a woman who drinks "only" a bottle of wine per night is at the same risk threshold as a man consuming considerably more.

Trauma as the Missing Link

For many women, the pathway to dual diagnosis runs directly through trauma. The National Center for PTSD reports that women are more than twice as likely as men to develop post-traumatic stress disorder following a traumatic event, and that sexual violence—experienced by approximately one in five American women—is among the most potent PTSD triggers. PTSD is itself one of the most common co-occurring conditions in women with substance use disorder, and the relationship between them is bidirectional: trauma increases the risk of substance use disorder, and substance use disorder increases exposure to traumatic events.

Yet in clinical settings, trauma history is frequently undercollected in women presenting with mood disorders or anxiety. When it is collected, the link between trauma, psychiatric symptoms, and substance use is not always drawn explicitly. A woman who developed alcohol dependence in her mid-twenties following a sexual assault may receive a depression diagnosis, an anxiety diagnosis, and eventually an alcohol use disorder diagnosis—but across three separate clinical encounters, with three different providers, none of whom synthesized the full picture into a coherent dual diagnosis formulation.

Sarah, forty-three, describes her experience this way: "Every doctor knew part of the story. My therapist knew about the assault. My psychiatrist knew about the depression and the Xanax. My gynecologist knew I was drinking too much. But no one talked to anyone else, and no one ever said, 'These things are connected, and here's a treatment that addresses all of them.' I had to figure that out myself, after about eight years."

How Clinician Assumptions Create Diagnostic Delay

Beyond structural issues, clinician-level assumptions about women and substance use contribute meaningfully to diagnostic delay. Several patterns emerge consistently in the research literature.

First, women are more likely than men to have their substance use normalized or minimized by providers. Alcohol use in particular is subject to different social framing depending on gender; a woman who drinks to manage stress may be seen as coping rather than dependent, particularly if she maintains employment and family responsibilities.

Second, women with substance use disorders are more likely to present with internalized symptoms—anxiety, depression, somatic complaints—rather than the externalized behaviors that more reliably trigger addiction screening in clinical settings. Screening tools such as the CAGE questionnaire and early versions of the AUDIT were validated predominantly on male populations and may underdetect problematic drinking in women.

Third, stigma operates differently for women with substance use disorders. Research from the Pew Research Center and addiction-specific surveys consistently shows that women who use substances are judged more harshly than men in equivalent circumstances—particularly women who are mothers. This stigma is not lost on patients. Women in clinical settings frequently underreport substance use out of fear of judgment, loss of custody, or professional consequences. Providers who do not create explicitly non-judgmental assessment environments may never receive accurate information.

Reproductive Health as a Dual Diagnosis Variable

Women's dual diagnosis presentations are also shaped by reproductive health factors that have no equivalent in male populations and that remain undertreated in most dual diagnosis protocols.

Perimenstrual dysphoric disorder (PMDD), perinatal depression, and perimenopause are each associated with elevated rates of both psychiatric symptoms and substance use. The hormonal fluctuations involved in each of these phases affect the same neurotransmitter systems—serotonin, GABA, dopamine—that underlie both mood regulation and addiction vulnerability. A woman whose psychiatric symptoms reliably worsen in the luteal phase of her menstrual cycle, or who develops severe postpartum anxiety that she manages with alcohol, is experiencing a hormonally mediated dual diagnosis presentation that most standard assessment tools are not designed to capture.

Perinatal substance use disorder, in particular, represents a dual diagnosis context with distinctive features and barriers. Pregnant and postpartum women face extraordinary levels of stigma and legal risk when disclosing substance use, which suppresses help-seeking at precisely the moment when intervention is most needed. Providers who work with pregnant patients are not consistently trained in dual diagnosis assessment, and the clinical focus on fetal outcomes can inadvertently subordinate the mother's psychiatric and addiction treatment needs.

What Better Care Looks Like

For women seeking dual diagnosis assessment and treatment, several practical considerations can help navigate a system that was not fully designed with them in mind.

Seek providers who use gender-responsive screening tools. The AUDIT-C has better sensitivity for alcohol use disorder in women than the original CAGE. Trauma-informed screening instruments such as the ACE questionnaire should be standard in any dual diagnosis assessment for female patients.

Request an integrated assessment that explicitly addresses the relationship between psychiatric symptoms, substance use, and any relevant reproductive health history. If a provider addresses each of these in separate compartments without connecting them, the assessment is incomplete.

For providers, the most impactful change may be the simplest: ask. Research consistently shows that women are more likely to disclose substance use when asked directly, in a non-judgmental manner, by a provider who has established a foundation of trust. The clinical encounter that surfaces a dual diagnosis is rarely the result of a sophisticated screening algorithm. It is usually the result of a clinician who created the conditions for an honest conversation.

Priya, now forty, received her integrated dual diagnosis treatment at thirty-five. She is four years into sustained recovery and describes the preceding decade as "being sick in a way nobody had a name for." The name existed. It simply took the clinical system five years to say it to her.